Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084 AND Treatment
64 results:

  • 1. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
    Takei S; Tanaka Y; Lin YT; Koyama S; Fukuoka S; Hara H; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Ueno T; Kojima S; Wakabayashi M; Sakamoto N; Kojima M; Kuwata T; Yoshino T; Nishikawa H; Mano H; Endo I; Shitara K; Kawazoe A
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38336371
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Exploring Co-occurring pole Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
    Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
    Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Caecal malakoplakia: a rare mimic of malignancy.
    Li Voon Chong J; Ali N
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262716
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
    André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
    JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated pole variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. pole-Mutant Colon cancer Treated with PD-1 Blockade Showing Clearance of Circulating Tumor DNA and Prolonged Disease-Free Interval.
    Bikhchandani M; Amersi F; Hendifar A; Gangi A; Osipov A; Zaghiyan K; Atkins K; Cho M; Aguirre F; Hazelett D; Alvarez R; Zhou L; Hitchins M; Gong J
    Genes (Basel); 2023 May; 14(5):. PubMed ID: 37239414
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in pMMR/MSS colorectal cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.
    Wang J; Xiu J; Farrell A; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Liu T; Oberley M; Spetzler D; Korn WM; Shen L; Lenz HJ
    Lancet Oncol; 2023 Feb; 24(2):151-161. PubMed ID: 36681091
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
    Wang H; Li ZW; Ou Q; Wu X; Nagasaka M; Shao Y; Ou SI; Yang Y
    Cancer Med; 2022 Jul; 11(13):2541-2549. PubMed ID: 35506567
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
    Antoniotti C; Germani MM; Rossini D; Lonardi S; Pietrantonio F; Santini D; Marmorino F; Allegrini G; Daniel F; Raimondi A; Borelli B; Zaniboni A; Conca V; Abraham J; Spetzler D; Maiello E; Boccaccino A; Passardi A; Giordano M; Tamburini E; Korn MW; Masi G; Cremolini C
    Eur J Cancer; 2022 May; 167():23-31. PubMed ID: 35366570
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The Current and Evolving Role of Immunotherapy in Metastatic colorectal cancer.
    Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R
    Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or pole-mutated metastatic or unresectable colorectal cancer.
    Oh CR; Kim JE; Hong YS; Kim SY; Ahn JB; Baek JY; Lee MA; Kang MJ; Cho SH; Beom SH; Kim TW
    Int J Cancer; 2022 Jun; 150(12):2038-2045. PubMed ID: 35179785
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Molecular characteristics of young-onset colorectal cancer in Vietnamese patients.
    Do MD; Nguyen TH; Le KT; Le LHG; Nguyen BH; Le KT; Doan TPT; Ho CQ; Nguyen HN; Tran TD; Vu HA
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):678-685. PubMed ID: 35098669
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
    Xiao W; Yuan Y; Wang S; Liao Z; Cai P; Chen B; Zhang R; Wang F; Zeng Z; Gao Y
    Front Immunol; 2021; 12():798451. PubMed ID: 35095878
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Microsatellite-Stable cancer Harboring a pole Mutation.
    Schenck K; Masetti M; Pfarr N; Lorenzen S
    Oncol Res Treat; 2022; 45(4):222-226. PubMed ID: 34875656
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer.
    Antill Y; Buchanan DD; Scott CL
    Cancer; 2022 Mar; 128(6):1157-1161. PubMed ID: 34875102
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
    Du F; Liu Y
    J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
    Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
    Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
    [TBL] [Abstract] [Full Text] [Related]  


    of 4.